N-Methyl-3,4-methylenedioxyamphetamine
"N-Methyl-3,4-methylenedioxyamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
| Descriptor ID |
D018817
|
| MeSH Number(s) |
D02.092.471.683.152.670
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "N-Methyl-3,4-methylenedioxyamphetamine".
Below are MeSH descriptors whose meaning is more specific than "N-Methyl-3,4-methylenedioxyamphetamine".
This graph shows the total number of publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in this website by year, and whether "N-Methyl-3,4-methylenedioxyamphetamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in Profiles.
-
Supportive Touch in Psychedelic Assisted Therapy. Am J Bioeth. 2025 Jan; 25(1):29-39.
-
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep. 2024 11 14; 14(1):28022.
-
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res. 2024 May; 335:115886.
-
Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA). Am J Ther. 2024 Mar-Apr 01; 31(2):e141-e154.
-
Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. Am J Ther. 2024 Mar-Apr 01; 31(2):e97-e103.
-
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology. 2022 11 15; 219:109214.
-
Acute ascending aortic dissection after MDMA/ecstasy use: A case report. Hellenic J Cardiol. 2016 Sep - Oct; 57(5):351-354.
-
Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of drug-induced psychotic symptoms. Addict Biol. 2010 Jul; 15(3):365-7.
-
MDMA (ecstasy) modulates locomotor and prefrontal cortex sensory evoked activity. Brain Res. 2009 Dec 11; 1302:175-82.
-
Enhanced intensity dependence and aggression history indicate previous regular ecstasy use in abstinent polydrug users. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13; 33(8):1484-90.